Teva Pharmaceutical Industries Limited (TLV:TEVA)
| Market Cap | 111.06B |
| Revenue (ttm) | 55.55B |
| Net Income (ttm) | 2.36B |
| Shares Out | n/a |
| EPS (ttm) | 2.04 |
| PE Ratio | 47.04 |
| Forward PE | 11.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,352,788 |
| Average Volume | 1,468,279 |
| Open | 9,638.00 |
| Previous Close | 9,670.00 |
| Day's Range | 9,599.00 - 9,824.00 |
| 52-Week Range | 4,865.00 - 9,824.00 |
| Beta | 0.67 |
| RSI | 78.64 |
| Earnings Date | Jan 28, 2026 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
Financial Performance
In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.
Financial numbers in USD Financial StatementsNews
JP Morgan Raises Price Target for TEVA to $35, Maintains Overweight Rating | TEVA Stock News
JP Morgan Raises Price Target for TEVA to $35, Maintains Overweight Rating | TEVA Stock News
Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead?
Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.
Teva Pharmaceutical (TEVA) to Remove Over 200 Patents from FDA's Orange Book
Teva Pharmaceutical (TEVA) to Remove Over 200 Patents from FDA's Orange Book
Teva seeks removal of over 200 patents from FDA Orange Book after FTC challenge
Teva (TEVA) Requests FDA to Remove Over 200 Patent Listings
Teva (TEVA) Requests FDA to Remove Over 200 Patent Listings
TEVA Stock Rating Update: B of A Securities Raises Price Target to $32 | TEVA Stock News
TEVA Stock Rating Update: B of A Securities Raises Price Target to $32 | TEVA Stock News
TEVA Stock: Barclays Initiates Coverage with Overweight Rating | TEVA Stock News
TEVA Stock: Barclays Initiates Coverage with Overweight Rating | TEVA Stock News
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play
Teva holds bullish momentum, trading above key SMAs, as branded drugs and biosimilars drive growth despite generics softness.
Glenview Doubles Down on Teva Stock With $72 Million Buy, According to Recent SEC Filing
Share count rose by 868,457; position value increased by $71.98 million Post-trade stake: 16,692,680 shares valued at $337.19 million Holding now comprises 7.51% of fund AUM, making it the fund's 4th-...
Teva Pharmaceuticals Submits NDA For Olanzapine LAI
(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced the submission of a New Drug Application to the FDA for olanzapine extended-release injectab...
Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
PARSIPPANY, N.J. and TEL AVIV, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the submis...
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's
Sandoz, Teva and Dr. Reddy's emerge as standouts as generic drugmakers lean on biosimilars, complex generics and tighter cost controls.
Unpacking the Latest Options Trading Trends in Teva Pharmaceutical Indus
Whales with a lot of money to spend have taken a noticeably bullish stance on Teva Pharmaceutical Indus . Looking at options history for Teva Pharmaceutical Indus (NYSE: TEVA) we detected 9 trades. I...
Teva Pharmaceutical (TEVA) Receives a Boost in Price Target by Goldman Sachs | TEVA Stock News
Teva Pharmaceutical (TEVA) Receives a Boost in Price Target by Goldman Sachs | TEVA Stock News
3 Generic Drug Stocks to Watch Amid Changing U.S. Landscape
Generic drugmakers face U.S. pricing pressure, but TEVA, SDZNY and RDY gain momentum through complex generics and biosimilars.
Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q3 2025 Update
Duquesne Family Office's ~$4.06B 13F portfolio remains concentrated, with the top five holdings—Natera, Insmed, Teva Pharma, Taiwan Semi, and...
Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue
Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two pharmaceutical companies moving in opposite directions. Pfizer is stabilizing af...
Teva Pharmaceutical (TEVA) Receives Sector Outperform Rating from Scotiabank | TEVA Stock News
Teva Pharmaceutical (TEVA) Receives Sector Outperform Rating from Scotiabank | TEVA Stock News
Teva Pharmaceutical Industries Ltd at Citi Global Healthcare Conference Transcript
Teva Pharmaceutical Industries Ltd at Citi Global Healthcare Conference Transcript
Israel Has Been Mired In Controversy During Its War With Hamas. Big Tech Investment Tells A Different Story.
Israel's stock market has outpaced U.S. markets since Oct. 7, 2023, with U.S.-traded leaders like Teva, Elbit Systems and Tower Semiconductor showing big gains.
TEVA Forecasts Significant Rise in Cash Flow by 2030
TEVA Forecasts Significant Rise in Cash Flow by 2030
Noteworthy ETF Inflows: IEFA, SPOT, SE, TEVA
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI EAFE ETF (Symbol: IEFA) where we have detected an ap...
30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks
Druckenmiller invests his personal and family's wealth through his fund, the Duquesne Family Office. Druckenmiller is high on biotech stocks, with his top three holdings at the end of the third quarte...
Is the Market Bullish or Bearish on Teva Pharmaceutical Industries Ltd?
Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) short interest as a percent of float has risen 6.52% since its last report. According to exchange reported data, there are now 50.39 million shares s...